End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4942 USD | +4.99% | -5.87% | -75.77% |
May. 14 | Transcript : The Oncology Institute, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 14 | The Oncology Institute, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Capitalization 1 | 714.2 | 122.8 | 150.4 | 36.79 | - |
Enterprise Value (EV) 1 | 714.2 | 108.8 | 150.4 | 36.79 | 36.79 |
P/E ratio | -60.9 x | - | - | - | - |
Yield | - | - | - | - | - |
Capitalization / Revenue | - | 0.49 x | 0.46 x | 0.09 x | 0.08 x |
EV / Revenue | - | 0.49 x | 0.46 x | 0.09 x | 0.08 x |
EV / EBITDA | - | -5.22 x | -5.83 x | -2.05 x | 20.6 x |
EV / FCF | - | -1.82 x | -3.68 x | -1.71 x | -1.71 x |
FCF Yield | - | -54.8% | -27.2% | -58.5% | -58.5% |
Price to Book | - | - | - | - | - |
Nbr of stocks (in thousands) | 73,249 | 74,421 | 73,749 | 74,438 | - |
Reference price 2 | 9.750 | 1.650 | 2.040 | 0.4942 | 0.4942 |
Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net sales 1 | - | 252.5 | 324.2 | 414.7 | 482.8 |
EBITDA 1 | - | -23.54 | -25.8 | -17.91 | 1.783 |
EBIT 1 | - | -79.96 | -77.02 | -23.67 | -3.824 |
Operating Margin | - | -31.67% | -23.75% | -5.71% | -0.79% |
Earnings before Tax (EBT) | - | - | - | - | - |
Net income 1 | -10.93 | 1.657 | -83.07 | -54.04 | -35.27 |
Net margin | - | 0.66% | -25.62% | -13.03% | -7.31% |
EPS | -0.1600 | - | - | - | - |
Free Cash Flow 1 | - | -67.28 | -40.88 | -21.51 | -21.53 |
FCF margin | - | -26.65% | -12.61% | -5.19% | -4.46% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | 64.98 | 71.42 | 76.19 | 80.22 | 82.04 | 85.79 | 94.67 | 103.3 | 107.5 | 109.1 |
EBITDA 1 | - | -6.68 | -4.641 | -7.929 | -6.941 | -5.35 | -6.252 | -10.94 | -3.915 | -1.364 | -1.694 |
EBIT 1 | - | -20.1 | -23.08 | -32.87 | -14.94 | -13.92 | -15.29 | -17.97 | -5.37 | -2.79 | -3.095 |
Operating Margin | - | -30.93% | -32.32% | -43.14% | -18.62% | -16.97% | -17.82% | -18.98% | -5.2% | -2.59% | -2.84% |
Earnings before Tax (EBT) | - | -2.698 | - | - | - | - | - | - | - | - | - |
Net income 1 | -5.453 | -2.674 | -9.502 | - | -16.9 | -17.42 | -18.75 | -19.89 | -13 | -10.4 | -10.75 |
Net margin | - | -4.12% | -13.3% | - | -21.06% | -21.23% | -21.86% | -21.01% | -12.58% | -9.67% | -9.85% |
EPS | -0.0600 | -0.0300 | - | - | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 8/9/22 | 11/9/22 | 3/9/23 | 5/10/23 | 8/8/23 | 11/8/23 | 3/27/24 | 5/14/24 | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|---|
Net Debt | - | - | - | - | - |
Net Cash position | - | 14 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - |
Free Cash Flow 1 | - | -67.3 | -40.9 | -21.5 | -21.5 |
ROE (net income / shareholders' equity) | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - |
Assets 1 | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - |
Capex 1 | - | 5.53 | 4.57 | 2.67 | 6.28 |
Capex / Sales | - | 2.19% | 1.41% | 0.64% | 1.3% |
Announcement Date | 3/10/22 | 3/9/23 | 3/27/24 | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-75.77% | 36.79M | |
+25.52% | 88.99B | |
-24.52% | 74.82B | |
-3.94% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+79.20% | 13.21B | |
+70.11% | 13.08B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- TOI Stock
- Financials The Oncology Institute, Inc.